Used in targeted cancer therapy, particularly for tumors overexpressing SLC34A2, such as ovarian and non-small cell lung cancers. Delivers cytotoxic agents directly to cancer cells by binding to the SLC34A2 transporter, minimizing damage to healthy tissues. Investigated in antibody-drug conjugates (ADCs) to enhance treatment specificity and efficacy. Also serves as a research tool for studying phosphate transport mechanisms in diseased cells.